KLOW 80mg — GHK-Cu + BPC-157 + TB-500 + KPV Research Blend

Zoom

85,00 €

Tax included • Free delivery from 99€

Almost sold out, alert me on restock

KLOW 80 mg is the advanced tetra-peptide formulation of our experimental cosmetic range: it fully reprises the synergistic logic of GLOW (GHK-Cu + BPC-157 + TB-500) while adding a fourth essential biological axis — modulation of chronic dermal inflammation — provided by the tripeptide KPV (Lys-Pro-Val). Cumulative concentration raised to 80 mg, including an increased GHK-Cu component to push matrix remodeling further, and the new KPV brick that covers a biological territory never addressed by classical regenerative peptides.

KLOW's rationale rests on a repeated field observation in dermato-experimental research: many relevant models are not simple "clean" wounds to heal, but tissues with an underlying chronic inflammatory component. Acne-prone skin, atopic eczema, psoriasis-like murine, contact dermatitis, inflammatory scalp, diabetic wounds with persistent leukocyte infiltrate — all these contexts share a common denominator that hampers classical remodeling: chronic NF-κB activation, sustained release of TNF-α, IL-6, IL-1β, and a tissue microarchitecture disturbed by immune infiltrate. GHK-Cu, BPC-157, and TB-500 work admirably on the repair cascade but do not actively suppress this inflammatory background noise. KPV, derived from the C-terminal of alpha-MSH, intervenes precisely on this register: blockade of NF-κB translocation, documented reduction of pro-inflammatory cytokines, direct antimicrobial activity against Candida and Staphylococcus aureus.

Our 80 mg reference is co-lyophilized with a majorizing GHK-Cu concentration, BPC-157 and TB-500 in synergistic proportion, and KPV added according to a calibrated ratio to cover the inflammatory component without dominating the remodeling signal. HPLC > 98% certificate of analysis on each component. The format targets laboratories working on experimental models of inflammatory dermatoses (induced eczema, imiquimod psoriasis, acne cornea), hair research on inflammatory ground (alopecia areata, seborrheic dermatitis), and longitudinal cutaneous remodeling studies over 8-16 weeks requiring an increased work volume. Strictly Research Use Only (RUO) positioning.

Science

01
Mechanism of action

KLOW's mechanistic basis adds the three axes of GLOW (already widely documented in the GLOW product sheet) to a fourth dedicated axis — that of the KPV tripeptide, which deserves specific development.

Reminder of GLOW's three axes (not redundant here). GHK-Cu (increased dose): transcriptomic modulation via more than 4,192 genes (Pickart-Margolina 2015), upregulation of collagen I/III, elastin, proteoglycans, copper-dependent SOD, downregulation of senescence and inflammation. BPC-157: structured angiogenesis via VEGF-R2 and eNOS (Chang 2011), functional tissue perfusion. TB-500: migration of keratinocytes and fibroblasts via reversible G-actin sequestration (Safer 1991), release of the pro-angiogenic tetrapeptide AcSDKP. In KLOW, the increased GHK-Cu proportion accentuates the transcriptomic axis, and the addition of KPV introduces the fourth dimension.

KPV: chemical nature and alpha-MSH lineage. KPV is the tripeptide Lys-Pro-Val, i.e., the C-terminal fragment (positions 11-13) of alpha-melanocyte-stimulating hormone alpha-MSH, itself derived from the POMC precursor. The complete alpha-MSH sequence is Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 (13 amino acids). It is therefore a minimalist fragment of 3 amino acids, molecular mass 342.4 Da, remarkably small to be active. This structural compactness explains several key properties: efficient tissue penetration, superior enzymatic stability to long peptides, and documented oral activity (although less potent than via parenteral route).

KPV anti-inflammatory mechanism. The central documented mechanism is inhibition of nuclear translocation of NF-κB, master transcription factor of the inflammatory response. Thomas Luger's group in Münster showed from the 1990s onward that complete alpha-MSH and its fragments (including KPV) modulate the production of TNF-α, IL-6, and IL-1β in keratinocytes and Langerhans cells. Work by Mark Dalmasso and Didier Merlin at Emory University then documented in 2008 (Gastroenterology) the anti-inflammatory activity of KPV in murine ulcerative colitis models with remarkable oral efficacy. In dermato-research, Bassi 2016 and Taylor 2004 synthesized cutaneous data: reduction of inflammatory erythema, decrease of edema, restoration of the epidermal barrier in induced dermatitis models.

Direct antimicrobial activity. Beyond the anti-inflammatory action, KPV presents documented antimicrobial activity against Candida albicans, Staphylococcus aureus, and certain E. coli strains. This mechanism would involve disturbance of the microbial membrane and/or inhibition of fungal ergosterol synthesis. In the cutaneous research context, this dual activity (anti-inflammatory + antimicrobial) is particularly relevant for acne models (Cutibacterium acnes, S. aureus), seborrheic dermatitis (Malassezia), and colonized wounds.

Four-part synergy and feedback loops. KLOW's guiding principle is that chronic dermal inflammation compromises the efficacy of classical regenerative peptides: a tissue with sustained NF-κB activation secretes metalloproteinases (MMP-2, MMP-9) that actively degrade the new collagen deposited by fibroblasts stimulated by GHK-Cu. Suppression of this inflammatory noise via KPV therefore frees biological space for GHK-Cu, BPC-157, and TB-500 to express their full potential. We move from simple synergy (three additive axes) to second-order synergy (KPV potentiates the phenotypic expression of the other three by removing an underlying inflammatory brake).

Alpha-MSH-like positioning without pigmentary effect. Critical point: unlike Melanotan-2 which targets melanogenesis via MC1R, KPV (fragment 11-13 of alpha-MSH) does NOT have significant melanogenic activity. The critical motif for MC1R activation is concentrated in the central Phe-Arg-Trp segment (positions 7-9) of alpha-MSH, totally absent from KPV. KPV retains the anti-inflammatory and antimicrobial activity of alpha-MSH but loses its pigmentary activity. This is exactly what makes KPV interesting in inflammatory cutaneous research: immunomodulatory action without collateral pigmentary modification.

Clinical data

02Clinical studies

The literature applicable to KLOW is structured in two blocks: the base already covered in the GLOW sheet (GHK-Cu, BPC-157, TB-500), which we do not fully reprise here, and the KPV-specific corpus that justifies the very existence of this extended reference.

KPV — origin and alpha-MSH lineage (1980-2010). The first work on short alpha-MSH fragments dates to the 1980s in the laboratories of Anna Catania in Milan and James Lipton in Chicago, following the demonstration that complete alpha-MSH was a powerful endogenous anti-inflammatory (Lipton 1997 Trends Neurosci). The natural question was: what is the smallest sequence that retains anti-inflammatory activity? The work of the 1990s progressively identified the C-terminal tripeptide KPV (positions 11-13) as the minimal functional core, with concomitant loss of melanogenic activity (which resides in the central Phe-Arg-Trp sequence, positions 7-9). Hiltz and Lipton 1990 (FASEB J) formalize this dissociation.

KPV in dermato-research (1998-2024). Luger et al. in Münster publish in 1998 (J Leukoc Biol) the first data on modulation of pro-inflammatory cytokines in human keratinocytes under KPV. Taylor 2004 (Ann N Y Acad Sci) synthesizes the state of research on alpha-MSH fragments in experimental dermatology: atopic dermatitis, allergic contact, and psoriasis-like murine models. Bassi 2016 (Peptides journal) reviews recent cutaneous data: reduction of erythema, edema, neutrophilic infiltrate in multiple models. The volume of KPV cutaneous literature remains modest compared to "major" cosmetic peptides, but is qualitatively solid and converges on a reproducible anti-inflammatory profile.

KPV in intestinal and IBD research (2008-2024). The major turn for KPV came from experimental gastroenterology. Dalmasso-Merlin 2008 (Gastroenterology 134:1) publish a pivotal work demonstrating oral anti-colitis activity of KPV in the murine DSS model, with spectacular reduction of macroscopic and histological severity. This publication opens a series of works on experimental IBD (inflammatory bowel disease): Kannengiesser 2008, Merlin 2014, Paiva 2018. KPV's oral activity (linked to its compactness and passage via intestinal PepT1 transporters) generated industrial interest for oral cosmetic "from within" formulations, widely publicized but whose clinical validation remains limited.

Antimicrobial KPV (2000-2024). Thomas Luger's group documented from 1999 (Cutler J Invest Dermatol) direct antimicrobial activity of KPV against Candida albicans and Staphylococcus aureus. Subsequent works (Wong 2003, Brzoska 2008) confirmed and broadened the antimicrobial spectrum. This activity is distinct from the anti-inflammatory effect and operates via direct membrane disruption. In cutaneous research practice, this dual activity is exploited in acne models (C. acnes) and seborrheic dermatitis (Malassezia).

Cosmetic multi-peptide blends with KPV. The specific GHK-Cu + BPC-157 + TB-500 + KPV combination has not been the subject of controlled publication to our knowledge. It is an empirical construction by regenerative medicine research laboratories, mechanistically rationalized but not RCT-validated. As with GLOW, this reality is honestly acknowledged: the biological rationale is strong, integrated data remain to be produced, and this is precisely what justifies availability of such a reference in exploratory research format.

Relation to Melanotan and differentiation precautions. It is important for a reader to clearly distinguish KPV from the family of melanogenic alpha-MSH analogs (Melanotan-1, Melanotan-2, afamelanotide). The latter are designed to maximize MC1R activation and therefore melanogenesis, which implies conservation and optimization of the central Phe-Arg-Trp segment. KPV, devoid of this segment, shares with Melanotan the alpha-MSH lineage but diverges radically in pharmacological profile: anti-inflammatory and antimicrobial, not melanogenic.

No references yet for this peptide — search PubMed for associated scientific literature.

The listed studies are provided for documentation and research purposes only. They do not constitute a therapeutic indication nor a recommendation for human use. This product is strictly for laboratory use only (RUO).

Lab workflow

03
Research protocols

KLOW protocols take up the general logic of injectable cosmetic blends with adaptation for the increased concentration (80 mg vs 70 mg for GLOW) and integration of the KPV component. The formulation is designed to cover long exploratory cycles (8-16 weeks) or models requiring an increased work volume.

Reconstitution. Add 3 ml of 0.9% bacteriostatic water (benzyl alcohol preserved) to the 80 mg lyophilized vial, pouring slowly against the inner wall. Final concentration: approximately 26.7 mg/ml total (approximate distribution: 19 mg/ml GHK-Cu + 3.3 mg/ml BPC-157 + 3.3 mg/ml TB-500 + 1.1 mg/ml KPV). Gently swirl until complete dissolution (1-2 minutes). The solution must be clear and pale-blue to pale blue-green, identical to GLOW — coloration remains dominated by the GHK-Cu copper complex, KPV being chemically neutral in coloration. Note the reconstitution date on the vial.

Dosing and volume per injection.
- 0.1 ml of solution = 2.67 mg total (1.9 mg GHK-Cu + 0.33 mg BPC + 0.33 mg TB-500 + 0.11 mg KPV)
- 0.15 ml = 4 mg total (2.85 mg GHK-Cu + 0.5 mg BPC + 0.5 mg TB-500 + 0.165 mg KPV)
- 0.2 ml = 5.34 mg total (3.8 mg GHK-Cu + 0.66 mg BPC + 0.66 mg TB-500 + 0.22 mg KPV)

KPV doses per injection (110-220 mcg) are consistent with dermato literature (typically 100-500 mcg of pure KPV in cutaneous research). The KPV proportion in the blend is deliberately moderate to avoid shifting the response profile toward a pure anti-inflammatory at the expense of remodeling.

Documented schedules.

Schedule A - Experimental inflammatory dermatosis protocol (eczema, psoriasis-like, induced dermatitis): 0.15 ml SC daily for 4-6 weeks, with injection close to the study zone (local SC rather than systemic). Monitoring of erythema, cutaneous thickness, standardized clinical scores. Consumption: 4.2-6.3 ml over 28-42 days, requires 2 vials for a full cycle.

Schedule B - Long remodeling protocol on inflammatory ground (inflammatory aged skin, chronic heliosis, post-acne): 0.1 ml SC daily for 8-12 weeks. Recommended cycle for longitudinal studies with weekly standardized photographic assessment. Consumption: 5.6-8.4 ml, requires 2-3 vials.

Schedule C - Hair protocol on inflammatory ground (experimental alopecia areata, seborrheic scalp dermatitis): 0.1-0.15 ml SC pericranial (mesotherapy technique), twice weekly, 12-16-week cycle. Consumption: 3-5 ml over 12-16 weeks, one vial suffices.

Schedule D - Complicated cicatrization protocol (experimental diabetic wounds, chronic ulcers): 0.15 ml SC at the lesion periphery, 3 times per week, until closure or end of experimental phase. Variable consumption depending on duration.

Experimental topical route. As with GLOW, incorporation into a cream base (cold cream or serum) at 0.1-0.2% total peptide is conceivable for accessory cosmetic uses, but trans-epidermal bioavailability remains low (1-5%). For the KPV component specifically, oral literature (Dalmasso 2008) suggests better enzymatic stability than other components: liposomal topical formulations could theoretically increase penetration, but this exceeds the scope of our standard reference.

Cycles and pauses. 8-16-week cycles with 3-4-week pauses. Given the addition of KPV (anti-inflammatory), researchers working on chronic inflammatory models may document a post-cycle duration of remanence superior to that of pure GLOW, KPV seeming to durably normalize the dermal NF-κB axis.

Reconstitution for this format (80 mg)Standard volumes used in laboratory settings

Water added	Concentration	Reading marker
3 ml	26,67 mg/ml	10 UI = 2,67 mg
5 ml	16 mg/ml	10 UI = 1,6 mg

The volume of water does not change the product, only its concentration. Introduce the water slowly along the vial wall, never directly onto the lyophilisate, then swirl without shaking. Markers given on a 1 ml syringe graduated in 100 units.

Asepsis

Disinfect surfaces and stoppers (70% alcohol).

Solvent

Draw the required volume of bacteriostatic water.

Introduction

Inject gently against the vial wall (avoid direct jet on powder).

Solubilization

Roll the vial gently. Do not shake vigorously (degradation risk).

Solution storageOnce reconstituted: 2-8°C (refrigerator).

WarningTheoretical tool for chemical handling. Does not constitute medical advice.

I open the dilution calculator

What is normal on arrivalThe observations that worry customers, and are not defects

The amount of powder looks tiny. A lyophilisate takes up a few millimetres at the bottom of the vial, sometimes just a translucent film. The stated weight is there.
The powder is compact, stuck to the wall or to the stopper. Transport moves the freeze-dried cake around. It changes nothing to reconstitution.
The vial carries no individual label. That is our standard packaging, not a downgraded vial.
After reconstitution, deposits or filaments appear. This is common, especially with small molecules. Let it settle and roll the vial between your palms, never shake it.
The parcel is plain. Nothing on the outside indicates the contents or the brand name.

What is not normal: a cracked vial, an uncrimped cap or a stopper that moves, powder that has liquefied or changed colour. In those specific cases, write to us with a photo and we take the vial back.

Handling

04Storage & handling

KLOW extends the GLOW blend with a fourth peptide (KPV) whose stability must be integrated into global conservation reasoning. The good news: KPV is the smallest and most stable of the four components.

Unopened lyophilized powder. Optimal storage at -20 degrees, original packaging, protected from direct light. Documented stability 24 months. Acceptable refrigerated storage 2-8 degrees for 12-18 months. Controlled room temperature 15-25 degrees: 3-6 months maximum. As with GLOW, the lyophilized cake must present a slight bluish tint (due to GHK-Cu); a totally white or greenish-brownish cake would be abnormal.

Reconstituted vial — component stability hierarchy.
1. KPV: most stable in aqueous solution (short tripeptide, stabilizing central Pro bond, >21 days without documented degradation)
2. GHK-Cu: stable thanks to the copper complex that rigidifies the structure (>14 days, moderate photosensitivity)
3. TB-500: intermediate stability (10-14 days comfortably)
4. BPC-157: most fragile (14-21 days, progressive degradation beyond)

The limiting component is therefore BPC-157, identical to GLOW. Practical stability of the reconstituted blend: 14-21 days refrigerated 2-8 degrees, protected from light, in the original vial.

Visual degradation signs. Fresh solution: very-pale-blue to pale blue-green tint. Warning signs identical to GLOW: shift to brown/dark-green (copper oxidation), particles/turbidity (contamination or precipitation), total loss of coloration (complex dissociation). In all these cases, discard the vial.

Freeze-thaw cycles. Lyophilized powder: tolerates several short out-and-back cold cycles. Reconstituted solution: NEVER freeze. Freezing degrades GHK-Cu (copper complex dissociation), BPC-157 (denaturation), TB-500 (aggregation). KPV alone would tolerate freezing, but the other components do not.

Light protection. Same rule as GLOW: keep the vial in its cardboard sleeve or an aluminum pouch in the refrigerator. UV = priority enemy of the GHK-Cu complex.

"Double vial" strategy for long cycles (8-16 weeks). For a long protocol of Schedule B type (8-12 weeks), it may be pragmatic to:
1. Fully reconstitute the first vial (80 mg / 3 ml) and use over the first 14-21 days
2. Keep the second lyophilized vial in the freezer
3. Reconstitute the second vial at the start of week 3-4, just before exhaustion or expiration of the first

This strategy maintains optimal BPC-157 activity throughout the cycle, avoiding the "degradation plateau" of a single vial used over 5-6 weeks.

Transport and reception. Identical protocol to GLOW. Lyophilized powder travels 48-72h at ambient temperature without major impact. Upon receipt of a visually abnormal cake, photograph and contact the laboratory before reconstitution.

Expiration. Indicated on the vial label, typically 12-18 months from manufacturing date for refrigerated storage. For -20-degree storage, an additional 6-12-month margin is documented.

01When to choose KLOW over GLOW?

Choose KLOW when the experimental model presents a chronic inflammatory component: acne-prone skin, eczema, psoriasis-like, seborrheic dermatitis, inflammatory scalp, complicated wounds with leukocyte infiltrate. For healthy moderately aged skin or standard clean cicatrization, GLOW suffices and saves the KPV component. In doubt about the ground, KLOW is the prudent choice: the KPV component is well tolerated and has no documented unfavorable effect on non-inflammatory tissues.

02Is KPV a 'anti-inflammatory Melanotan'?

KPV derives from the same alpha-MSH precursor as Melanotan-2, but the two molecules diverge radically. KPV corresponds to the C-terminal 11-13 fragment of alpha-MSH which carries anti-inflammatory and antimicrobial activity. Melanotan-2 is a modified analog of the central 7-9 segment of alpha-MSH which carries melanogenic activity. KPV has NO significant pigmentary effect: the critical sequence for MC1R activation (Phe-Arg-Trp) is not in KPV. These two peptides share an ancestry but have practically nothing in common in research practice.

03Can I switch from GLOW to KLOW during the protocol?

Technically possible. If the experimental protocol evolves toward a need for an anti-inflammatory component (e.g., appearance of an unforeseen inflammatory ground, model that worsens), switching to KLOW after exhaustion of the GLOW vial is feasible without wash-out. In a rigorous research approach, document the transition in the protocol and consider this change as a change of experimental group rather than strict continuation. Do not simultaneously mix GLOW and KLOW in the same syringe: peptide proportions would be uncontrolled.

04Is the solution color different between GLOW and KLOW?

No, the pale blue to pale blue-green coloration remains identical between GLOW and KLOW as it originates exclusively from the GHK-Cu copper-peptide complex. KPV, BPC-157, and TB-500 are optically transparent in solution. The only theoretical visual difference would be a slightly more intense tint in KLOW due to the increased GHK-Cu concentration, but in practice the difference is barely perceptible to the eye.

05Does KPV work orally? Can KLOW be taken orally?

Isolated KPV is documented as orally active (Dalmasso 2008, Gastroenterology) thanks to its small size and passage via intestinal PepT1 transporters. However, KLOW also contains BPC-157 (partially orally active) and GHK-Cu + TB-500 (not orally active, degraded by gastric proteases). The oral route for KLOW would deliver only KPV and perhaps BPC-157, completely losing the GHK-Cu and TB-500 axes. KLOW is designed for injection (SC or ID). Oral route is not recommended for this blend.

06Is there an interaction risk between KPV and the other peptides?

No documented unfavorable interaction. The four peptides act on distinct biological targets (cutaneous transcriptome for GHK-Cu, VEGF-R2 for BPC-157, G-actin for TB-500, NF-κB for KPV) without direct pharmacological overlap. The only documented 'interaction' is indirect and favorable: KPV reduces the activity of MMP-2/9 metalloproteinases secreted under inflammation, which protects the new collagen deposited under GHK-Cu stimulation. This is precisely the second-order synergy logic of the blend.

07How long to observe an effect on experimental inflammatory dermatosis?

The KPV component acts relatively quickly on inflammatory markers (observable erythema and edema reduction at 7-14 days in acute models). GHK-Cu/BPC-157/TB-500 components have slower kinetics (measurable matrix remodeling at 4-8 weeks). In a chronic inflammatory dermatosis model, one typically observes: weeks 1-2 visible inflammatory reduction, weeks 3-6 epidermal barrier restoration and progressive infiltrate reduction, weeks 6-12 integrative matrix remodeling and return to a functional cutaneous profile. Longitudinal studies therefore document evaluation windows calibrated at 2 / 6 / 12 weeks.

08Can KLOW be used without a particular inflammatory component?

Yes, but GLOW would be more coherent in this case: KLOW adds KPV which is specifically interesting on inflammatory ground. On healthy or moderately aged tissue without significant inflammation, KPV remains without unfavorable effect but its utility is marginal: there is no active NF-κB to modulate. In a protocol without an explicit inflammatory component, GLOW is the logical and economical choice. Reserve KLOW for cases where the inflammatory component is either established or suspected.

Benchmark

Similar peptides

KLOW fits into a precise cosmetic peptide landscape. Positioning the blend against direct and indirect competitors clarifies real indications and limits.

KLOW vs GLOW. The most obvious comparison, and the most important to clarify. GLOW (70 mg, tri-peptide) covers the three axes of classical cutaneous remodeling: matrix, perfusion, migration. KLOW (80 mg, tetra-peptide) adds the fourth anti-inflammatory KPV brick. Choose GLOW for: healthy or moderately aged skin without marked inflammatory component, clean cicatrization protocols, basic cosmetic research. Choose KLOW for: acne-prone skin, atopic eczema, psoriasis-like, seborrheic dermatitis, inflammatory scalp, complicated wounds with leukocyte infiltrate, integrative experimental dermatitis models. For a researcher without certainty about the ground, KLOW is the prudent default choice, the KPV component having no documented unfavorable effect on non-inflammatory tissues.

KLOW vs KPV alone. Isolated KPV literature is primarily gastroenterological (experimental IBD) with a more limited cutaneous branch. For a study targeted on the pure anti-inflammatory axis (without remodeling component), isolated KPV is the rigorous reference. KLOW is relevant when the objective is to associate anti-inflammation with active remodeling, i.e., when the experimental model includes both inflammatory pathology and a need for tissue reconstruction — by far the most frequent situation in experimental dermatology.

KLOW vs topical corticosteroids (hydrocortisone, mometasone, clobetasol). Corticosteroids are the reference cutaneous anti-inflammatories in clinical dermatology. Their short-term efficacy is superior to that of KPV, but they present several limitations: cutaneous atrophy in prolonged use, rebound on discontinuation, inhibition of cicatrization (diametrically opposed to GHK-Cu/BPC/TB-500), systemic risks in absorbing zones. KLOW and corticosteroids are not direct competitors but different strategies: corticosteroids for rapid short-term relief, KLOW for integrative long-term remodeling on inflammatory ground.

KLOW vs topical JAK inhibitors (ruxolitinib, tofacitinib). Topical JAK inhibitors are the new anti-inflammatory generation in atopic dermatitis and alopecia areata. Completely different mechanism (direct pharmacological inhibition of JAK-STAT pathway vs MC receptor modulation by KPV). JAK inhibitors are powerful but specialized on the JAK-STAT axis, without regenerative component. KLOW is more versatile but less powerful on the JAK-STAT side alone if that is the main axis of the pathology studied.

KLOW vs anti-inflammatory cutaneous peptides (Thymulin, Thymosin Alpha-1). Thymulin and Thymosin Alpha-1 are peptides of thymic origin with immunomodulatory properties. Their profile is more systemic than local, and their mechanism more "global" (immune restoration) than "local" (dermal NF-κB blockade). They may complement KLOW in immunodeficiency models with cutaneous manifestation but do not substitute for KLOW for targeted experimental dermatology research.

KLOW vs melanotan-2 or afamelanotide. Possible confusion for a non-expert reader: all three derive distantly from alpha-MSH. KLOW contains KPV (C-terminal fragment 11-13) = anti-inflammatory and antimicrobial, NOT pigmentary. Melanotan-2 / afamelanotide are modified analogs of the central segment (Phe-Arg-Trp) = powerfully pigmentary. The two families have practically nothing in common in research practice, despite the distant filiation.

Realistic positioning. KLOW is a specialized tool for integrative experimental dermatology research, particularly suited to models where chronic inflammation coexists with a need for remodeling. It is not "better" than GLOW in absolute terms — it is better on a specific phenotype (inflammatory ground), and equivalent or slightly excessive on a non-inflammatory phenotype. The choice depends entirely on the target experimental model. When in doubt and for a laboratory wanting to cover broadly, KLOW is the default encompassing choice.

Klow 80mg Skin & Beauty

Skin Tissues

01
Mechanism of action

02Clinical studies

03
Research protocols

Asepsis

Solvent

Introduction

Solubilization

04Storage & handling

Similar peptides

Skin Tissues

Asepsis

Solvent

Introduction

Solubilization

Complementary reagents